Cardiac Catheterization Clinical Trial
— TRACE-NLOfficial title:
Evaluation of the Safety, Efficacy and Cost-effectiveness of Transcatheter Tricuspid Valve Repair in Patients With Severe Tricuspid Regurgitation in the Netherlands.
Verified date | February 2024 |
Source | St. Antonius Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a national multicenter, open-label, randomized controlled trial to show superiority of edge-to-edge Transcatheter Tricuspid Valve repair (TTVr) on top of the Standard Of Care (SOC; heart failure medication) over the SOC alone in patients with symptomatic severe Tricuspid Regurgitation (TR) in the Netherlands.
Status | Enrolling by invitation |
Enrollment | 150 |
Est. completion date | November 1, 2027 |
Est. primary completion date | November 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The patient is symptomatic (New York Heart Association Functional Class II, III or ambulatory class IV) despite Standard Of Care (SOC). The Central Screening Committee (CSC) will assess whether the patient is receiving SOC. The CSC will also ensure that in case of the presence of atrial fibrillation, left sided heart valve disease (not requiring intervention) or coronary artery disease, conditions are first treated adequately with medication and/or (surgical) intervention. 2. The patient suffers from = grade 3 isolated TR as determined by the assessment of a qualifying transthoracic echocardiogram (TTE) and three-dimensional transesophageal echocardiogram (3DTEE) and confirmed by the CSC, according to European Association for Percutaneous Cardiovascular Interventions (Tricuspid Focus Group) consensus document (in press). Note: If cardiac procedure(s) occur after eligibility was determined, TR grade will be re-assessed 30 days after the procedure. 3. The cardiac surgeon of the sites' local heart team concurs that the patient is at high estimated risk for mortality or morbidity with TV surgery. 4. The patient is =18 years of age at time of consent. 5. The patient must provide written informed consent prior to any trial related procedure. Exclusion Criteria: 1. Systolic pulmonary artery pressure (sPAP) > 70 mmHg or fixed pre-capillary pulmonary hypertension as assessed by right heart catheterization. Severe uncontrolled hypertension Systolic Blood Pressure (SBP) = 180 mmHg and/or Diastolic Blood Pressure (DBP) = 110 mmHg. 2. Any condition that would interfere with a TTVr procedure, such as prior tricuspid valve repair or tricuspid valve leaflet anatomy which may preclude device implantation (e.g. calcification in grasping area, a severe coaptation defect of the tricuspid leaflets (no clip placement possible), pacemaker or Implantable Cardioverter Defibrillator (ICD) leads that would prevent appropriate placement or visualization of TTVr devices, Ebstein Anomaly (normal annulus position, but valve leaflets attached to walls and septum of the right ventricle), tricuspid valve anatomy non evaluable by echo, known allergy or hypersensitivity to dual antiplatelet therapy AND anticoagulant therapy or to device materials, femoral venous mass or thrombus or vegetation. 3. Indication for left-sided (e.g. severe aortic stenosis, severe mitral regurgitation) or pulmonary valve correction within prior 60 days. Note: concomitant mitral valve disease (e.g. mitral regurgitation) will be treated first and patients will be reassessed for the trial after 60 days. 4. Tricuspid valve stenosis - Defined as a tricuspid valve orifice of = 1.0 cm2 and/or mean gradient =5 mmHg. 5. Left Ventricular Ejection Fraction (LVEF) =20% 6. Active endocarditis, active rheumatic heart disease, other ongoing infection requiring antibiotic therapy (enrolment possible 30 days after discontinuation of antibiotics with no active infection) or leaflets degenerated from rheumatic disease (i.e. noncompliant, perforated) 7. Myocardial infarction known unstable angina, or percutaneous coronary intervention within prior 30 days. 8. Hemodynamic instability defined as systemic systolic pressure <90 mmHg with or without afterload reduction, cardiogenic shock or the need for inotropic support or hemodynamic support device (e.g. intra-aortic balloon pump). 9. Cerebrovascular Accident (CVA) within prior 90 days 10. Chronic dialysis 11. Bleeding disorders or hypercoagulable state, inability to use dual antithrombotic therapy due to contraindication, allergy or hypersensitivity 12. Active peptic ulcer or active gastrointestinal (GI) bleeding 13. Life expectancy of less than 12 months 14. Subject currently participating in another clinical trial (not yet completed primary endpoint) or in another clinical investigation for valvular heart disease. 15. Pregnant or nursing patients or those who plan pregnancy during the course of the trial. Women of childbearing age are required to have a negative pregnancy test 7 days prior to baseline visit. Women of childbearing age should be instructed to use safe contraception or have a sterilized regular partner. 16. Presence of anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the eye of the investigator, limits the subject's ability to participate in the clinical investigation or comply with follow-up requirements, or impact the scientific soundness of the investigation results. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amsterdam UMC | Amsterdam | |
Netherlands | UMC Groningen | Groningen | |
Netherlands | Leiden UMC | Leiden | |
Netherlands | Maastricht UMC+ | Maastricht | |
Netherlands | St. Antonius Hospital Nieuwegein | Nieuwegein | |
Netherlands | Erasmus University Medical Center | Rotterdam |
Lead Sponsor | Collaborator |
---|---|
St. Antonius Hospital | ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hierarchical composite of all-cause mortality, heart failure hospitalization and Quality of Life | Quality of Life is measured with the Kansas City Cardiomyopathy Questionnaire with a 5 point change as clinically significant (0-100 points, higher score is better outcome) | 12 months | |
Secondary | All-cause mortality | Mortality of any cause | 12 months | |
Secondary | Hospitalization for heart failure | Hospitalization for acute decompensated heart failure | 12 months | |
Secondary | Change in Kansas City Cardiomyopathy Questionnaire | 5 point change is considered clinically significant (0-100 points with higher score is a better outcome), change of 5 points in Kansas City Cardiomyopathy Questionnaire is considered clinically meaningful | 12 months | |
Secondary | Number of participants without Major Adverse Events (MAE) | Cardiovascular mortality, myocardial infarction, stroke, major bleeding, device embolisation, new onset renal failure, endocarditis requiring surgery, non-elective cardiovascular surgery for device related adverse events. | 30 days and 12 months | |
Secondary | Change in New York Heart Association | ranging from 0 to 4 (no limitation to severe limitation) | 12 months | |
Secondary | Change in 6-Minute Walk Test | Distance in meters (higher score is a better outcome) | 12 months | |
Secondary | Reduction tricuspid regurgitation | Echocardiographic assessment of Tricuspid Regurgitation (at least from severe to moderate or less) | 30 days, 6 months and 12 months | |
Secondary | Cost-effectiveness as assessed by the Markov model | The investigators will compare the cost-effectiveness of the intervention group versus the control group based on lifetime horizon by constructing a Markov model with model parameters populated from the trial results as well as other published literature. The model will estimate the incremental cost-effectiveness ratio between the two groups | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05539092 -
The Effect of Changing Angle of Bed on Pain Severity and Vascular Complications Among Cardiac Catheterization Patients
|
N/A | |
Completed |
NCT02074527 -
CHAIN_brazilian Registry of Congenital HeArt Disease INtervention and Angiography
|
||
Completed |
NCT01157338 -
Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization
|
N/A | |
Terminated |
NCT00850473 -
PET/CT Study in the Diagnosis of Coronary Plaque
|
N/A | |
Completed |
NCT03645837 -
Rapid Clamp Release Post Trans-radial Cardiac Catheterization
|
N/A | |
Completed |
NCT04404257 -
Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation
|
N/A | |
Recruiting |
NCT03555500 -
Fasting or Non Fasting for Cardiac Catheterization
|
N/A | |
Not yet recruiting |
NCT06134141 -
The Outcome of Interventional Cardiac Catheterization In Pediatric Cardiology Unit, Assiut University Heart Hospital
|
||
Recruiting |
NCT05941013 -
Ultrasound-detectable Endotracheal Tube: a Feasibility Study
|
N/A | |
Recruiting |
NCT05632640 -
Post Anesthesia Care Unit (PACU) Weighted Blanket Study
|
N/A | |
Unknown status |
NCT00838175 -
Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access
|
N/A | |
Completed |
NCT03243942 -
Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement
|
Phase 2 | |
Completed |
NCT01155167 -
Topical Radial Artery Vasodilation
|
Phase 2/Phase 3 | |
Completed |
NCT04258007 -
Sugammadex Versus Neostigmine in Pediatric Less Than Two Years Undergoing Cardiac Catheterization
|
N/A | |
Withdrawn |
NCT00825331 -
Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)
|
N/A | |
Recruiting |
NCT05225077 -
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
|
Phase 4 | |
Completed |
NCT05117359 -
Transcatheter Para-Valvular Leak Closures
|
||
Recruiting |
NCT00849940 -
Validation of Brain Oxygenation Monitor on Pediatric Patients
|
N/A | |
Active, not recruiting |
NCT05364463 -
Effect of Reactive Hyperemia and Ultrasound-guided Puncture on the Success Rate of Radial Artery Cannulation (RadialHUS)
|
N/A | |
Completed |
NCT03245255 -
Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound
|
Phase 2 |